Hangzhou Venture Capital Association Visited ConVerd in 2024 Unicorn Company Tour Series

June 27, 2024 – ConVerd Pharmaceuticals recently welcomed a delegation from the Hangzhou Venture Capital Association (HVCA) under the guidance of the Hangzhou Science and Technology Bureau. Led by Mr. Fu Qiang, Executive Vice President of HVCA, the visit brought together over 20 representatives from member institutions for in-depth discussions with ConVerd's team.

During the event, Mr. Fu Qiang and Dr. Hu Fang, Founder of ConVerd, engaged in dynamic and productive exchanges. Dr. Hu shared ConVerd's journey in oncolytic virus drug development, from early clinical discoveries to next-generation drug design, and from challenges in tumor immunotherapy to the progressive advancement of systemic immunotherapy. Mr. Fu expressed sincere admiration for ConVerd's decade of perseverance in staying true to its mission and conveyed high expectations for the breakthrough efficacy of ConVerd's oncolytic virus pipeline. Attendees also voiced their enthusiasm for multi-faceted collaboration to support ConVerd's innovative endeavors.

This visit marks the beginning of a new chapter in collaboration between ConVerd and HVCA, laying a solid foundation for future partnerships.